Literature DB >> 28065475

Could the RTS,S/AS01 meningitis safety signal really be a protective effect of rabies vaccine?

Bradford D Gessner1, Darryn L Knobel2, Anne Conan2, Adam Finn3.   

Abstract

The RTS,S/AS01 malaria vaccine has been associated with meningitis and cerebral malaria safety signals. Key characteristics of the meningitis signal include presence, in the 5-17month but not the 6-12week age group, of delayed and variable meningitis onset after vaccination, and multiple etiologies. For both meningitis and cerebral malaria, the 5-17month old age group control arm had abnormally low incidences while other arms in both age groups had meningitis and cerebral malaria incidences similar to background rates. No single hypothesis postulating an adverse effect from RTS,S/AS01 unites these observations. Unlike the 6-12week group, the control population in the 5-17month old age group received rabies vaccine. This raises the possibility that non-specific rabies vaccine effects had a protective effect against central nervous system infection, a hypothesis consistent with the epidemiologic data. The lack of a confirmed biologic mechanism for such an effect emphasizes the need for additional studies.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adverse events; Central nervous system infection; Immunization; Malaria; Meningitis; Non-specific effects; Rabies; Safety; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 28065475     DOI: 10.1016/j.vaccine.2016.12.067

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Distinct Helper T Cell Type 1 and 2 Responses Associated With Malaria Protection and Risk in RTS,S/AS01E Vaccinees.

Authors:  Gemma Moncunill; Maxmillian Mpina; Augusto J Nhabomba; Ruth Aguilar; Aintzane Ayestaran; Héctor Sanz; Joseph J Campo; Chenjerai Jairoce; Diana Barrios; Yan Dong; Núria Díez-Padrisa; José F Fernandes; Salim Abdulla; Jahit Sacarlal; Nana A Williams; Jaroslaw Harezlak; Benjamin Mordmüller; Selidji T Agnandji; John J Aponte; Claudia Daubenberger; Clarissa Valim; Carlota Dobaño
Journal:  Clin Infect Dis       Date:  2017-09-01       Impact factor: 9.079

2.  Pediatric Cerebral Malaria.

Authors:  Geoffrey Guenther; Daniel Muller; Dominic Moyo; Douglas Postels
Journal:  Curr Trop Med Rep       Date:  2021-01-25

3.  Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.

Authors:  Yolanda Guerra Mendoza; Elodie Garric; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Jean-Yves Pirçon; Jens-Ulrich Stegmann; Pascale Vandoolaeghe; Lucas Otieno; Walter Otieno; Seth Owusu-Agyei; Jahit Sacarlal; Nahya Salim Masoud; Hermann Sorgho; Marcel Tanner; Halidou Tinto; Innocent Valea; Ali Takadir Mtoro; Patricia Njuguna; Martina Oneko; Godfrey Allan Otieno; Kephas Otieno; Samwel Gesase; Mary J Hamel; Irving Hoffman; Seyram Kaali; Portia Kamthunzi; Peter Kremsner; Miguel Lanaspa; Bertrand Lell; John Lusingu; Anangisye Malabeja; Pedro Aide; Pauline Akoo; Daniel Ansong; Kwaku Poku Asante; James A Berkley; Samuel Adjei; Tsiri Agbenyega; Selidji Todagbe Agnandji; Lode Schuerman
Journal:  Hum Vaccin Immunother       Date:  2019-04-23       Impact factor: 3.452

4.  TIPICO IX: report of the 9th interactive infectious disease workshop on infectious diseases and vaccines.

Authors:  Federico Martinón-Torres; Xavier Bosch; Rino Rappuoli; Shamez Ladhani; Esther Redondo; Timo Vesikari; Adolfo García-Sastre; Irene Rivero-Calle; José Gómez-Rial; Antonio Salas; Carlos Martín; Adam Finn; Robb Butler
Journal:  Hum Vaccin Immunother       Date:  2019-06-03       Impact factor: 3.452

5.  Sex-differential non-specific effects of adjuvanted and non-adjuvanted rabies vaccines versus placebo on all-cause mortality in dogs (NERVE-Dog study): a study protocol for a randomized controlled trial with a nested case-control study.

Authors:  Darryn L Knobel; Anne Conan; Felix N Toka; Sintayehu M Arega; Charles Byaruhanga; Eric Ogola; Erick M O Muok; Jan E Crafford; Andrew L Leisewitz; Melvyn Quan; Mary Anna Thrall
Journal:  BMC Vet Res       Date:  2022-10-01       Impact factor: 2.792

6.  Choices in vaccine trial design in epidemics of emerging infections.

Authors:  Rebecca Kahn; Annette Rid; Peter G Smith; Nir Eyal; Marc Lipsitch
Journal:  PLoS Med       Date:  2018-08-07       Impact factor: 11.069

7.  Non-specific effects of rabies vaccine on the incidence of common infectious disease episodes: study protocol for a randomized controlled trial.

Authors:  Darryn Knobel; Christianah Ibironke Odita; Anne Conan; Donna Barry; Marshalette Smith-Anthony; Juliet Battice; Shianne England; Bradford D Gessner
Journal:  Trials       Date:  2020-06-16       Impact factor: 2.279

8.  Making sense of emerging evidence on the non-specific effects of the BCG vaccine on malaria risk and neonatal mortality.

Authors:  Quique Bassat; Gemma Moncunill; Carlota Dobaño
Journal:  BMJ Glob Health       Date:  2020-03-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.